ALKERMES reported $0.09 in EPS Earnings Per Share for its fiscal quarter ending in September of 2026.


Fiscal Calendar Actual Consensus Previous Date
FY2026Q3 Sep/2026 0.09 0.01 0.49 Nov/03
FY2026Q2 Jun/2026 -0.02 0.52 Jul/28
FY2026Q1 Mar/2026 -0.40 -0.4 0.13 May/05
FY2025Q4 Dec/2025 0.29 0.42 1.05 Feb/25
FY2025Q3 Sep/2025 0.49 0.4 0.73 Oct/28




Eps Change Date
AbbVie USD 3.82 0.17 Sep/2026
Acadia Pharmaceuticals USD 0.31 0.13 Sep/2026
ALKERMES USD 0.09 0.09 Sep/2026
Amgen USD 6.45 0.16 Sep/2026
Biogen USD 2.62 0.98 Sep/2026
BioMarin Pharmaceutical USD 0.23 0.97 Sep/2026
Bristol-Myers Squibb USD 1.35 0.69 Sep/2026
Coherus Biosciences USD -0.43 0.06 Dec/2025
Eli Lilly USD 7.48 0.9 Sep/2026
Gilead Sciences USD 2.55 9.3 Sep/2026
Heron Therapeutics USD -0.02 0.02 Dec/2025
Ionis Pharmaceuticals USD 0.66 1.35 Sep/2026
J&J USD 2.7 0.2 Sep/2026
Malin Corporation EUR -0.06 0.1 Dec/2023
Merck USD 2.49 2.62 Sep/2026
Minerva Neurosciences USD -0.56 3.53 Dec/2024
Nektar Therapeutics USD -1.78 0.43 Mar/2026
Neurocrine Biosciences USD 3.29 0.44 Sep/2026
Otsuka Holdings JPY 202.96 19.8 Sep/2026
Ovoca Bio EUR 0 0.06 Dec/2025
Pfizer USD 0.87 0.1 Sep/2026
Regeneron Pharmaceuticals USD 20.07 5.78 Sep/2026
Vertex Pharmaceuticals USD 4.76 0.03 Sep/2026